Emyria Limited is an Australia-based clinical services and drug development company. The Company is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. It delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The Company is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.

• Revenue in AUD (TTM)1.95m
• Net income in AUD-11.95m
• Incorporated2018
• Employees--

• Location
  Emyria LtdD2 661 Newcastle StreetLEEDERVILLE 6007AustraliaAUS
• Phone+61 86559-2800
• Fax+61 86559-2829
• Websitehttps://www.emeraldclinics.com.au/